PREVESTDENPRO Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹71.81 Cr
verification pending
Revenue YoY
13.9%
reported change
EBITDA
₹29.62 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Prevest Denpro delivered steady FY26 results with 13.9% revenue growth to ₹71.81 Cr, driven by robust export expansion of 17.58% (countering domestic headwinds that saw only 9% growth). The company successfully navigated geopolitical disruptions affecting Q4 exports, with quarterly revenue growth moderating to 2.63% due to Middle East tensions impacting UAE subsidiary launch and shipping disruptions. However, profitability surprised positively—Q4 PAT grew 13.23% YoY while EBITDA margin expanded to 40.87%, demonstrating strong operational efficiency and cost discipline. Key strategic initiatives include digital dentistry expansion (40.5% revenue growth in 3D printing), new product launches from R&D pipeline (2 products launched, 4 test licenses in progress), and scaling UAE/US subsidiaries. With installed capacity for ₹125 Cr turnover (currently at 67-68% utilization for traditional products), the company has meaningful operating leverage available. Risks include near-term revenue concentration in exports and delayed international subsidiary ramp-up.
Colored figures show movement against the previous available record.
Guidance to track
- Company is developing a fully indigenous 3D printer through combination of in-house R&D and strategic global partnerships, positioning Prevest as a comprehensive digital dentistry solution provider.
- R&D pipeline contains 4 products at technology readiness level 7 (market-ready), including endodontic irrigants, self-curing resins, and periodontal gels, with 2 products already launched and additional launches planned.
- Management projects 40% of all dental procedures will involve digital workflows within 5 years, with digital dentistry positioned as primary growth driver and investment priority.
Risks flagged
- Q4 revenue from operations grew only 2.63% YoY compared to full-year 13.9%, reflecting geopolitical headwinds from Middle East tensions disrupting UAE subsidiary operations and export shipping schedules.
- When asked directly about R&D spending percentage, management (via Dr. Kalyan) declined to provide the number, stating 'we don't have the exact number yet' despite having detailed pipeline updates—potentially indicating inadequate tracking or disclosure.
- UAE subsidiary commercial operations delayed by 2+ months due to regional geopolitical tensions; registration completed but online sales yet to commence as of Q4 call, representing drag on international expansion timeline.
- Orodoc oral care brand saw 2% sales decline due to GST changes, Dubai municipality registration delays post-conflict, and inability to export planned consignment after Dubai exhibition was disrupted—management characterized FY27 as recovery year for this segment.
Key quotes
- Our focus on operational efficiency resulted in further improvement in margins during the quarter. EBITDA margin improved to 40.87%—demonstrating our ability to protect profitability even under difficult market condition.
- When it comes to digital dentistry everyone is at the same level probably we are slightly ahead than the other MNCs... we've seen around 40% increase in the revenue this year on 3D printing agents. We are also actively working on the 3D printer project so that we have a totally indigenous 3D printer by 2028.
- The cost of production in India is so low and their input duties are so high they can never beat us on price and the quality surely since we have good quality management certificates that proves the quality.
Research modules